New radiation combo shows promise for tough lung cancers
NCT ID NCT05615142
First seen May 16, 2026 · Last updated May 16, 2026
Summary
This early-phase study tests whether combining low-dose radiation with targeted radiation (SBRT) and an immunotherapy drug (PD-1 inhibitor) is safe for people with advanced non-small cell lung cancer who have not responded to standard treatments. Nine participants will receive this combination therapy to monitor side effects and see if it helps control the disease. The goal is to find a new treatment option for those with limited choices.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
West China Hospital, Sichuan University
Chengdu, Sichuan, 610041, China
Conditions
Explore the condition pages connected to this study.